Barinthus Biotherapeutics plc annual free cash flow
2020
2021
2022
2023
2024
2025
Barinthus Biotherapeutics plc Free Cash Flow (FCF) History (BRNS)
Barinthus Biotherapeutics plc reported −$48.0M in free cash flow for fiscal 2025, a decrease of $18.2M from the previous fiscal year.
View full Barinthus Biotherapeutics plc company overviewBarinthus Biotherapeutics plc free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$48.0M | −$18.2M | — | — |
| 2024 | 2024-12-31 | −$29.8M | $26.5M | — | −199.29% |
| 2023 | 2023-12-31 | −$56.3M | −$35.8M | — | −7024.69% |
| 2022 | 2022-12-31 | −$20.6M | $13.2M | — | −46.01% |
| 2021 | 2021-12-31 | −$33.7M | −$22.4M | — | −12585.45% |
| 2020 | 2020-12-31 | −$11.3M | — | — | −234.83% |
Barinthus Biotherapeutics plc quarterly free cash flow
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$8.1M | $10.1M | — | — |
| Q1 2026 | 2026-03-31 | −$3.4M | $11.5M | — | — |
| Q4 2025 | 2025-12-31 | −$4.2M | −$17.1M | — | — |
| Q3 2025 | 2025-09-30 | −$10.7M | $7.6M | — | — |
| Q2 2025 | 2025-06-30 | −$18.1M | −$5.9M | — | — |
| Q1 2025 | 2025-03-31 | −$14.9M | −$2.8M | — | — |
| Q4 2024 | 2024-12-31 | $12.8M | $32.6M | — | — |
| Q3 2024 | 2024-09-30 | −$18.3M | −$7.1M | — | −122.33% |
| Q2 2024 | 2024-06-30 | −$12.2M | $7.8M | — | — |
| Q1 2024 | 2024-03-31 | −$12.1M | −$6.4M | — | — |
| Q4 2023 | 2023-12-31 | −$19.8M | −$7.8M | — | — |
| Q3 2023 | 2023-09-30 | −$11.2M | −$20.7M | — | — |
| Q2 2023 | 2023-06-30 | −$20.0M | −$9.5M | — | −5982.04% |
| Q1 2023 | 2023-03-31 | −$5.7M | $2.0M | — | −1213.89% |
| Q4 2022 | 2022-12-31 | −$11.9M | −$3.5M | — | −184.75% |
| Q3 2022 | 2022-09-30 | $9.5M | $11.6M | — | +153.74% |
| Q2 2022 | 2022-06-30 | −$10.4M | $4.4M | — | −61.23% |
| Q1 2022 | 2022-03-31 | −$7.7M | $690,000 | — | −51.08% |
| Q4 2021 | 2021-12-31 | −$8.4M | −$3.3M | — | — |
| Q3 2021 | 2021-09-30 | −$2.1M | −$1.3M | — | −11294.74% |
| Q2 2021 | 2021-06-30 | −$14.8M | −$13.8M | — | −42360.00% |
| Q1 2021 | 2021-03-31 | −$8.4M | −$4.0M | — | −3888.84% |
| Q4 2020 | 2020-12-31 | −$5.1M | — | — | −1438.14% |
| Q3 2020 | 2020-09-30 | −$891,000 | — | — | −27.41% |
| Q2 2020 | 2020-06-30 | −$996,000 | — | — | −194.91% |
| Q1 2020 | 2020-03-31 | −$4.3M | — | — | −616.03% |
Barinthus Biotherapeutics plc free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$11.3M to −$48.0M, a net decrease of $36.7M. Barinthus Biotherapeutics plc's latest reported quarter, Q2 2026, generated −$8.1M in free cash flow, an increase of $10.1M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Barinthus Biotherapeutics plc filings at SEC.gov ↗